David L.
- Country
- France
- Department
- Hepato-Gastroenterology and digestive oncology, CMC Magellan
Research Overview
- Comparison of Vedolizumab, Filgotinib, Ustekinumab, and Infliximab as First-Line Advanced Therapy to Maintain Remission in Patients with Ulcerative Colitis
- One-Year Real-World Effectiveness of Subcutaneous Guselkumab in Adults with Crohn’s Disease
- A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants with Moderately to Severely Active Ulcerative Colitis
Data & Insights
Has run more than one trial at 303 of 529 partner sites.
Specializations
Inflammatory Bowel Disease Management
The investigator specializes in treating inflammatory bowel diseases, with particular focus on both ulcerative colitis and Crohn's disease.
- Therapeutic Drug Monitoring
- Biologic Therapy Assessment
- Disease Activity Evaluation
Expertise in evaluating therapeutic responses and optimizing treatment strategies for moderate to severe cases.
Novel Treatment Approaches
Focuses on investigating innovative therapeutic interventions including fecal microbiota transplantation and emerging biological agents.
- Advanced Biological Therapies
- Microbiome-Based Treatments
- Combination Therapy Strategies
Explores cutting-edge treatment modalities for patients with refractory disease conditions.
Clinical Response Assessment
Specializes in evaluating treatment efficacy through comprehensive assessment of clinical, endoscopic, and biomarker outcomes.
- Endoscopic Evaluation
- Biomarker Monitoring
- Remote Patient Monitoring
Implements advanced monitoring techniques to optimize therapeutic outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.